米非司酮改善胰岛素抵抗个体的脂肪组织胰岛素敏感性
本研究为随机双盲安慰剂对照交叉试验,纳入16例超重/肥胖伴糖耐量异常但无临床高皮质醇血症的个体,予以米非司酮50mg每6小时或安慰剂治疗9天。结果显示米非司酮未改变全身葡萄糖处置的胰岛素敏感性指标,但显著改善脂肪组织胰岛素敏感性指数并降低脂肪胰岛素抵抗,同时降低肝胰岛素抵抗指数(P=0.08)。
要点
- 短期米非司酮改善脂肪组织胰岛素敏感性及脂肪胰岛素抵抗。
- 米非司酮未改变全身葡萄糖处置的胰岛素敏感性指标。
- 米非司酮增加胰岛素清除,不影响胰岛素分泌或β细胞葡萄糖敏感性。
核心结论
- 短期米非司酮改善无高皮质醇血症的肥胖高血糖个体的脂肪及肝脏胰岛素敏感性。
研究设计与样本
- 随机双盲安慰剂对照交叉研究,纳入16例超重/肥胖伴糖尿病前期或轻度2型糖尿病但无临床高皮质醇血症的个体。
- 米非司酮50mg每6小时或安慰剂治疗9天,洗脱6至8周后交叉至另一治疗组。
主要发现
- 米非司酮未改变全身葡萄糖处置的胰岛素敏感性指标(SI、MI、OGIS)。
- 米非司酮显著改善脂肪组织胰岛素敏感性指数(Adipo-SI:61.7 ± 32.9 vs 42.8 ± 23.9;P = 0.002)。
- 米非司酮显著降低脂肪胰岛素抵抗(adipo-IR:49.9 ± 45.9 vs 65.5 ± 43.8;P = 0.004)。
- 米非司酮降低肝胰岛素抵抗指数(HIRI:50.2 ± 38.7 vs 70.0 ± 44.3;P = 0.08)。
- 米非司酮增加胰岛素清除,但不影响胰岛素分泌或β细胞葡萄糖敏感性。
临床怎么用
- 对于超重/肥胖伴糖耐量异常但无临床高皮质醇血症者,短期米非司酮可能改善脂肪组织及肝脏胰岛素敏感性。
- 米非司酮对全身葡萄糖处置的胰岛素敏感性无显著影响,临床决策需结合个体情况。
局限性
- 样本量较小(n=16),结论需在更大规模研究中验证。
- 研究为期9天,长期疗效与安全性未知。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Increased tissue cortisol availability has been implicated in abnormal glucose and fat metabolism in patients with obesity, metabolic syndrome, and type 2 diabetes (T2DM). Our objective was to evaluate whether blockade of glucocorticoid receptor (GR) with mifepristone ameliorates insulin resistance (IR) in overweight/obese subjects with glucose intolerance. METHODS: We conducted a randomized, double-blinded, placebo-controlled, crossover study in overweight/obese individuals (n = 16, 44% female) with prediabetes or mild T2DM but not clinical hypercortisolism. Mifepristone (50 mg every 6 h) or placebo was administered for 9 days, followed by crossover to the other treatment arm after a washout period of 6 to 8weeks. At baseline and following each treatment, oral glucose tolerance test (OGTT) and frequently sampled intravenous glucose tolerance test (FSIVGTT) were performed. Insulin sensitivity was measured using FSIVGTT [primary outcome: insulin sensitivity index (SI)] and OGTT [Matsuda index (MI) and oral glucose insulin sensitivity index (OGIS)]. Hepatic and adipose insulin resistance were assessed using hepatic insulin resistance index (HIRI), and adipose tissue insulin sensitivity index (Adipo-SI) and adipo-IR, derived from the FSIVGTT. RESULTS: Mifepristone administration did not alter whole-body glucose disposal indices of insulin sensitivity (SI, MI, and OGIS). GR blockade significantly improved Adipo-SI (61.7 ± 32.9 vs 42.8 ± 23.9; P = 0.002) and reduced adipo-IR (49.9 ± 45.9 vs 65.5 ± 43.8; P = 0.004), and HIRI (50.2 ± 38.7 vs 70.0 ± 44.3; P = 0.08). Mifepristone increased insulin clearance but did not affect insulin secretion or β-cell glucose sensitivity. CONCLUSION: Short-term mifepristone administration improves adipose and hepatic insulin sensitivity among obese individuals with hyperglycemia without hypercortisolism.
引用
- Gubbi S, Muniyappa R, Sharma ST, et al. Mifepristone Improves Adipose Tissue Insulin Sensitivity in Insulin Resistant Individuals. J Clin Endocrinol Metab. 2021. PMID: 33507248. doi:10.1210/clinem/dgab046
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。